NYSEAMERICAN:STXS Stereotaxis (STXS) Stock Price, News & Analysis $2.50 +0.31 (+14.16%) Closing price 08/8/2025 04:10 PM EasternExtended Trading$2.49 -0.01 (-0.40%) As of 08/8/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About Stereotaxis Stock (NYSEAMERICAN:STXS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Stereotaxis alerts:Sign Up Key Stats Today's Range$2.29▼$2.5750-Day Range$2.04▼$2.5952-Week Range$1.54▼$2.72Volume1.12 million shsAverage Volume697,203 shsMarket Capitalization$215 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri. Read More Stereotaxis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreSTXS MarketRank™: Stereotaxis scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Stereotaxis. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Stereotaxis are expected to grow in the coming year, from ($0.26) to ($0.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stereotaxis is -8.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stereotaxis is -8.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStereotaxis has a P/B Ratio of 35.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.34% of the float of Stereotaxis has been sold short.Short Interest Ratio / Days to CoverStereotaxis has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.Change versus previous monthShort interest in Stereotaxis has recently increased by 5.07%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStereotaxis does not currently pay a dividend.Dividend GrowthStereotaxis does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.34% of the float of Stereotaxis has been sold short.Short Interest Ratio / Days to CoverStereotaxis has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.Change versus previous monthShort interest in Stereotaxis has recently increased by 5.07%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.43 News SentimentStereotaxis has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Stereotaxis this week, compared to 2 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Stereotaxis insiders have not sold or bought any company stock.Percentage Held by Insiders17.77% of the stock of Stereotaxis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.35% of the stock of Stereotaxis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Stereotaxis' insider trading history. Receive STXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stereotaxis and its competitors with MarketBeat's FREE daily newsletter. Email Address STXS Stock News HeadlinesStereotaxis, Inc. (STXS) Q2 2025 Earnings Call TranscriptAugust 8 at 2:10 PM | seekingalpha.comStereotaxis Reports 2025 Second Quarter Financial ResultsAugust 7 at 4:01 PM | globenewswire.comAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump policy move, and the other tied to a proven financial pattern that previously minted over 80,000 new millionaires. He believes a small $900 investment could turn into a $108,000 windfall within 12 months—and this may be the last chance for everyday investors to catch it. | Paradigm Press (Ad)Stereotaxis (STXS) Gets a Buy from TD CowenJuly 30, 2025 | theglobeandmail.comStereotaxis, Inc.: Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep CatheterJuly 28, 2025 | finanznachrichten.deStereotaxis Wins FDA Nod for CatheterJuly 28, 2025 | baystreet.caStereotaxis stock soars after FDA clearance for robotic mapping catheterJuly 28, 2025 | za.investing.comStereotaxis shares jump after FDA approves robotic mapping catheterJuly 28, 2025 | msn.comSee More Headlines STXS Stock Analysis - Frequently Asked Questions How have STXS shares performed this year? Stereotaxis' stock was trading at $2.29 on January 1st, 2025. Since then, STXS stock has increased by 9.2% and is now trading at $2.50. How were Stereotaxis' earnings last quarter? Stereotaxis Inc. (NYSEAMERICAN:STXS) announced its quarterly earnings data on Monday, November, 11th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.03. The firm had revenue of $9.20 million for the quarter, compared to analyst estimates of $6.80 million. Stereotaxis had a negative net margin of 73.43% and a negative trailing twelve-month return on equity of 354.30%. Read the conference call transcript. Who are Stereotaxis' major shareholders? Top institutional investors of Stereotaxis include Geode Capital Management LLC (1.72%), Prescott Group Capital Management L.L.C. (1.32%), Cherry Creek Investment Advisors Inc. (0.04%) and Intech Investment Management LLC (0.03%). View institutional ownership trends. How do I buy shares of Stereotaxis? Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Stereotaxis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stereotaxis investors own include Tesla (TSLA), Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Meta Platforms (META), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings11/11/2024Today8/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNYSEAMERICAN:STXS CIK1289340 Webwww.stereotaxis.com Phone(314) 678-6100Fax314-678-6159Employees130Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.05 million Net Margins-73.43% Pretax Margin-92.19% Return on Equity-354.30% Return on Assets-48.87% Debt Debt-to-Equity RatioN/A Current Ratio1.07 Quick Ratio0.66 Sales & Book Value Annual Sales$26.92 million Price / Sales7.99 Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book35.71Miscellaneous Outstanding Shares86,000,000Free Float70,719,000Market Cap$215 million OptionableNot Optionable Beta1.51 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSEAMERICAN:STXS) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stereotaxis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stereotaxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.